Related Experiment Video
Updated: Oct 9, 2025
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
Published on: July 25, 2025
Harnessing Macrophages through the Blockage of CD47: Implications for Acute Myeloid Leukemia
Luciana Melo Garcia1, Frédéric Barabé1,2
1MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, University of Texas, Houston, TX 77030, USA.
Abstract:
CD47 is a surface membrane protein expressed by all normal tissues. It is the so-called "don't eat me signal" because it protects the cells against phagocytosis. The CD47 interacts with the signal regulatory protein alpha (SIRPα) on the surface of macrophages, leading to downstream inhibitory signaling that dampens phagocytic capacity. Since macrophages exert immune surveillance against cancers, cancer cells overexpress CD47 to defend themselves against phagocytosis. Acute myeloid leukemia (AML) is a cancer of hematopoietic stem/progenitor cells (HSPC), and similar to other types of cancers, leukemic blasts show enhanced levels of CD47. In patients with AML, CD47 has been associated with a higher disease burden and poor overall survival. Blockage of CD47-SIRPα signaling leads to improved phagocytosis of AML cells and better overall survival in xenograft models. However, the introduction of a pro-phagocytic signal is needed to induce greater phagocytic capacity. These pro-phagocytic signals can be either Fc receptor stimulants (such as monoclonal antibodies) or natural pro-phagocytic molecules (such as calreticulin). Based on these pre-clinical findings, various clinical trials investigating the blockade of CD47-SIRPα interaction have been designed as monotherapy and in combination with other anti-leukemic agents. In this review, we will discuss CD47 biology, highlight its implications for AML pathophysiology, and explore the potential clinical translation of disrupting CD47-SIRPα to treat patients with AML.
Insights
Blocking the "don't eat me" signal CD47 in acute myeloid leukemia (AML) enhances macrophage-mediated cancer cell removal. Combining CD47 blockade with pro-phagocytic signals shows promise for improving AML patient survival.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- CD47 is a cell surface protein acting as a
- don't eat me
- signal, inhibiting macrophage phagocytosis via SIRPα interaction.
- Cancer cells, including those in acute myeloid leukemia (AML), overexpress CD47 to evade immune surveillance.
- Elevated CD47 levels in AML correlate with disease burden and reduced patient survival.
Purpose of the Study:
- To review the biology of CD47 and its role in AML pathophysiology.
- To explore the therapeutic potential of blocking the CD47-SIRPα interaction in AML treatment.
- To discuss the clinical translation of CD47-targeting strategies.
Main Methods:
- Review of pre-clinical findings on CD47-SIRPα signaling in AML.
- Analysis of xenograft models demonstrating improved phagocytosis and survival upon CD47 blockade.
- Examination of clinical trial designs for CD47-targeted therapies in AML.
Main Results:
- Blockade of CD47-SIRPα signaling enhances AML cell phagocytosis by macrophages.
- Combined blockade with pro-phagocytic signals may further improve therapeutic outcomes.
- Pre-clinical data supports the efficacy of CD47-SIRPα inhibition in AML models.
Conclusions:
- Targeting the CD47-SIRPα pathway represents a promising therapeutic strategy for AML.
- Combination therapies involving CD47 blockade and pro-phagocytic signals warrant further clinical investigation.
- Disrupting CD47-SIRPα interaction holds potential for improving survival in AML patients.
